Epigenetics in ovarian cancer

Methods in Molecular Biology

Volumn 863, Issue , 2012, Pages 253-269

  Seeber, L M S ^a   Van Diest, P J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Epigenetic biomarkers; Epigenetic therapies; Histone modification; Methylation; MicroRNA; Ovarian cancer

Indexed keywords

HISTONE; MICRORNA; TUMOR MARKER;

ARTICLE; BLOOD; CPG ISLAND; DNA METHYLATION; FEMALE; GENETIC EPIGENESIS; GENETICS; HUMAN; METABOLISM; OVARY TUMOR; PHYSIOLOGY; TUMOR SUPPRESSOR GENE;

CPG ISLANDS; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENES, TUMOR SUPPRESSOR; HISTONES; HUMANS; MICRORNAS; OVARIAN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

ANIMALIA;

EID: 84859942964     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-61779-612-8_15     Document Type: Article

References (109)

1. Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Thun, M.J. (2009) Cancer statistics, 2009. CA Cancer J. Clin. 59, 225-249.
2. Barnholtz-Sloan, J.S., Schwartz, A.G., Qureshi, F., Jacques, S., Malone, J., Munkarah, A.R. (2003) Ovarian cancer: Changes in patterns at diagnosis and relative survival over the last three decades. Am. J. Obstet Gynecol 189, 1120-1127. (Pubitemid 37373908)
3. Press, J.Z., De Luca, A., Boyd, N., Young, S., Troussard, A., Ridge, Y., Kaurah, P., Kalloger, S.E., Blood, K.A., Smith, M., Spellman, P.T., Wang, Y., Miller, D.M., Horsman, D., Faham, M., Gilks, C.B., Gray, J., Huntsman, D.G. (2008) Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer 8, 17.
4. Milde-Langosch, K., Ocon, E., Becker, G., Loning, T. (1998) p16/MTS1 inactivation in ovarian carcinomas: high frequency of reduced protein expression associated with hypermethylation or mutation in endometrioid and mucinous tumors. Int J Cancer 79, 61-65. (Pubitemid 28157728)
5. Balch, C., Huang, T.H., Brown, R., Nephew, K.P. (2004) The epigenetics of ovarian cancer drug resistance and resensitization. Am. J. Obstet Gynecol 191, 1552-1572. (Pubitemid 39491180)
6. Ibanez de Caceres, I., Battagli, C., Esteller, M., Herman, J.G., Dulaimi, E., Edelson, M.I., Bergman, C., Ehya, H., Eisenberg, B.L., Cairns, P.(2004) Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fl uid from ovarian cancer patients. Cancer Res. 64, 6476-6481. (Pubitemid 39297903)
7. Sellar, G.C., Watt, K.P., Rabiasz, G.J., Stronach, E.A., Li, L., Miller, E.P., Massie, C.E., Miller, J., Contreras-Moreira, B., Scott, D., Brown, I., Williams, A.R., Bates, P.A., Smyth, J.F., Gabra, H. (2003) OPCML at 11q25 is epigenetically inactivated and has tumor-suppressor function in epithelial ovarian cancer. Nat. Genet. 34, 337-343. (Pubitemid 36792869)
8. Feng, W., Marquez, R.T., Lu, Z., Liu, J., Lu, K.H., Issa, J.P., Fishman, D.M., Yu, Y., Bast, R.C. Jr. (2008) Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation. Cancer 112, 1489-1502. (Pubitemid 351441161)
9. Kwong, J., Lee, J.Y., Wong, K.K., Zhou, X., Wong, D.T., Lo, K.W., Welch, W.R., Berkowitz, R.S., Mok, S.C. (2006) Candidate tumor-suppressor gene DLEC1 is frequently downregulated by promoter hypermethylation and histone hypoacetylation in human epithelial ovarian cancer. Neoplasia 8, 268-278.
10. Petrocca, F., Iliopoulos, D., Qin, H.R., Nicoloso, M.S., Yendamuri, S., Wojcik, S.E., Shimizu, M., Di Leva, G., Vecchione, A., Trapasso, F., Godwin, A.K., Negrini, M., Calin, G.A., Croce, C.M. (2006) Alterations of the tumor suppressor gene ARLTS1 in ovarian cancer. Cancer Res. 66, 10287-10291. (Pubitemid 44799746)
11. Chien, J., Staub, J., Avula, R., Zhang, H., Liu, W., Hartmann, L.C., Kaufmann, S.H., Smith, D.I., Shridhar, V. (2004) Epigenetic silencing of TCEAL7 (Bex4) in ovarian cancer. Oncogene 24, 5089-5100.
12. Cvetkovic, D., Pisarcik, D., Lee, C., Hamilton, T.C., Abdollahi, A. (2004) Altered expression and loss of heterozygosity of the LOT1 gene in ovarian cancer. Gynecol Oncol 95, 449-455. (Pubitemid 39592503)
13. Pruitt, K., Ulku, A.S., Frantz, K., Rojas, R.J., Muniz-Medina, V.M., Rangnekar, V.M., Der, C.J., Shields, J.M. (2005) Ras-mediated loss of the pro-Apoptotic response protein Par-4 is mediated by DNA hypermethylation through Raf-independent and Raf-dependent signaling cascades in epithelial cells. J Biol. Chem. 280, 23363-23370. (Pubitemid 40853250)
14. Terasawa, K., Sagae, S., Toyota, M., Tsukada, K., Ogi, K., Satoh, A., Mita, H., Imai, K., Tokino, T., Kudo, R. (2004) Epigenetic inactivation of TMS1/ASC in ovarian cancer. Clin. Cancer Res. 10, 2000-2006. (Pubitemid 38375559)
15. Arnold, J.M., Cummings, M., Purdie, D., Chenevix-Trench, G. (2001) Reduced expression of intercellular adhesion molecule-1 in ovarian adenocarcinomas. Br J Cancer 85, 1351-1358. (Pubitemid 33081932)
16. Yuecheng, Y., Hongmei, L., Xiaoyan, X. (2006) Clinical evaluation of E-cadherin expression and its regulation mechanism in epithelial ovarian cancer. Clin Exp Metastasis ; 23, 65-74. (Pubitemid 44576780)
17. Backen, A.C., Cole, C.L., Lau, S.C., Clamp, A.R., McVey, R., Gallagher, J.T., Jayson, G.C. (2007) Heparan sulphate synthetic and editing enzymes in ovarian cancer. Br J Cancer 96, 1544-1548. (Pubitemid 46762949)
18. Staub, J., Chien, J., Pan, Y., Qian, X., Narita, K., Aletti, G., Scheerer, M., Roberts, L.R., Molina, J., Shridhar, V. (2007) Epigenetic silencing of HSulf-1 in ovarian cancer:implications in chemoresistance. Oncogene 26, 4969-4978. (Pubitemid 47172647)
19. Potapova, A., Hoffman, A.M., Godwin, A.K., Al-Saleem, T., Cairns, P. (2008) Promoter hypermethylation of the PALB2 susceptibility gene in inherited and sporadic breast and ovarian cancer. Cancer Res. 68, 998-1002. (Pubitemid 351272217)
20. Socha, M.J., Said, N., Dai, Y., Kwong, J., Ramalingam, P., Trieu, V., Desai, N., Mok, S.C., Motamed, K. (2009) Aberrant promoter methylation of SPARC in ovarian cancer. Neoplasia 11, 126-135.
21. Kikuchi, R., Tsuda, H., Kozaki, K., Kanai, Y., Kasamatsu, T., Sengoku, K., Hirohashi, S., Inazawa, J., Imoto, I. (2008) Frequent inactivation of a putative tumor suppressor, angiopoietin-like protein 2, in ovarian cancer. Cancer Res. 68, 5067-5075.
22. Kikuchi, R., Tsuda, H., Kanai, Y., Kasamatsu, T., Sengoku, K., Hirohashi, S., Inazawa, J., Imoto, I. (2007) Promoter hypermethylation contributes to frequent inactivation of a putative conditional tumor suppressor gene connective tissue growth factor in ovarian cancer. Cancer Res. 67, 7095-7105. (Pubitemid 47206536)
23. Baldwin, R.L., Nemeth, E., Tran, H., Shvartsman, H., Cass, I., Narod, S., Karlan, B.Y. (2000) BRCA1 promoter region hypermethylation in ovarian carcinoma: A population-based study. Cancer Res. 60, 5329-5333.
24. Strathdee, G., Appleton, K., Illand, M., Millan, D.W., Sargent, J., Paul, J., Brown, R. (2001) Primary ovarian carcinomas display multiple methylator phenotypes involving known tumor suppressor genes. Am. J. Pathol. 158, 1121-1127. (Pubitemid 32221804)
25. Catteau, A., Harris, W.H., Xu, C.F., Solomon, E. (1999) Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: Correlation with disease characteristics. Oncogene 18, 1957-1965. (Pubitemid 29150082)
26. Geisler, J.P., Hatterman-Zogg, M.A., Rathe, J.A., Buller, R.E. (2002) Frequency of BRCA1 dysfunction in ovarian cancer. J Natl. Cancer Inst. 94, 61-67. (Pubitemid 34082844)
27. Buller, R.E., Shahin, M.S., Geisler, J.P., Zogg, M., De Young, B.R., Davis, C.S. (2002) Failure of BRCA1 dysfunction to alter ovarian cancer survival. Clin. Cancer Res. 8, 1196-1202. (Pubitemid 34520421)
28. Rathi, A., Virmani, A.K., Schorge, J.O., Elias, K.J., Maruyama, R., Minna, J.D., Mok, S.C., Girard, L., Fishman, D.A., Gazdar, A.F. (2002) Methylation profi les of sporadic ovarian tumors and nonmalignant ovaries from high-risk women. Clin. Cancer Res. 8, 3324-3331. (Pubitemid 35340705)
29. Teodoridis, J.M., Hall, J., Marsh, S., Kannall, H.D., Smyth, C., Curto, J., Siddiqui, N., Gabra, H., McLeod, H.L., Strathdee, G., Brown, R. (2005) CpG island methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res. 65, 8961-8967. (Pubitemid 41377387)
30. Bol, G.M., Suijkerbuijk, K.P., Bart, J., Vooijs, M., van der Wall, E., van Diest, P.J. (2010) Methylation profi les of hereditary and sporadic ovarian cancer. Histopathology 57, 363-370.
31. Hilton, J.L., Geisler, J.P., Rathe, J.A., Hattermann-Zogg, M.A., DeYoung, B., Buller, R.E. (2002) Inactivation of BRCA1 and BRCA2 in ovarian cancer. J Natl. Cancer Inst. 94, 1396-1406. (Pubitemid 35154144)
32. Wilcox, C.B, Baysal, B.E., Gallion, H.H., Strange, M.A., DeLoia, J.A. (2005) Highresolution methylation analysis of the BRCA1 promoter in ovarian tumors. Cancer Genet Cytogenet 159, 114-122. (Pubitemid 40719379)
33. Gras, E., Cortes, J., Diez, O., Alonso, C., Matias-Guiu, X., Baiget, M., Prat, J. (2001) Loss of heterozygosity on chromosome 13q12-q14, BRCA-2 mutations and lack of BRCA-2 promoter hypermethylation in sporadic epithelial ovarian tumors. Cancer 92, 787-795. (Pubitemid 32783064)
34. Su, H.Y., Lai, H.C., Lin, Y.W., Chou, Y.C., Liu, C.Y., Yu, M.H. (2009) An epigenetic marker panel for screening and prognostic prediction of ovarian cancer. Int J Cancer 124, 387-393.
35. Fiegl, H., Windbichler, G., Mueller-Holzner, E., Goebel, G., Lechner, M., Jacobs, I.J., Widschwendter, M. (2008) HOXA11 DNA methylation-A novel prognostic biomarker in ovarian cancer. Int J Cancer 123, 725-729. (Pubitemid 351898435)
36. Wei, S.H., Chen, C.M., Strathdee, G., Harnsomburana, J., Shyu, C.R., Rahmatpanah, F., Shi, H., Ng, S.W., Yan, P.S., Nephew, K.P., Brown, R., Huang, T.H. (2002) Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifi es candidate epigenetic markers. Clin. Cancer Res. 8, 2246-2252. (Pubitemid 34753597)
37. Houshdaran, S., Hawley, S., Palmer, C., Campan, M., Olsen, M.N., Ventura, A.P., Knudsen, B.S., Drescher, C.W., Urban, N.D., Brown, P.O., Laird, P.W. (2010) DNA methylation profi les of ovarian epithelial carcinoma tumors and cell lines. PLoS One 5, e9359.
38. Akahira, J., Sugihashi, Y., Suzuki, T., Ito, K., Niikura, H., Moriya, T., Nitta, M., Okamura, H., Inoue, S., Sasano, H., Okamura, K., Yaegashi, N. (2004) Decreased expression of 14-3-3 sigma is associated with advanced disease in human epithelial ovarian cancer: Its correlation with aberrant DNA methylation. Clin. Cancer Res. 10, 2687-2693. (Pubitemid 38509143)
39. Akahira, J., Sugihashi, Y., Ito, K., Niikura, H., Okamura, K., Yaegashi, N. (2004) Promoter methylation status and expression of TMS1 gene in human epithelial ovarian cancer. Cancer Sci 95, 40-43. (Pubitemid 38208405)
40. Kaneuchi, M., Sasaki, M., Tanaka, Y., Shiina, H., Yamada, H., Yamamoto, R., Sakuragi, N., Enokida, H., Verma, M., Dahiya, R. (2005) WT1 and WT1-AS genes are inactivated by promoter methylation in ovarian clear cell adenocarcinoma. Cancer 104, 1924-1930. (Pubitemid 41513176)
41. Kaneuchi, M., Sasaki, M., Tanaka, Y., Shiina, H., Verma, M., Ebina, Y., Nomura, E., Yamamoto, R., Sakuragi, N., Dahiya, R. (2004) Expression and methylation status of 14-3-3 sigma gene can characterize the different histological features of ovarian cancer. Biochem Biophys Res Commun 316, 1156-1162. (Pubitemid 38369074)
42. Ehrlich, M. (2006) Cancer-linked DNA hypomethylation and its relationship to hypermethylation. Curr Top Microbiol Immunol 310, 251-274. (Pubitemid 47400293)
43. Feinberg, A.P., Vogelstein, B. (1983) Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 301(5895):89-92. (Pubitemid 13154475)
44. Gama-Sosa, M.A., Midgett, R.M., Slagel, V.A., Githens, S., Kuo, K.C., Gehrke, C.W., Ehrlich, M. (1983) Tissue-specific differences in DNA methylation in various mammals. Biochim Biophys Acta 740, 212-219. (Pubitemid 13078586)
45. Strathdee, G., Vass, J.K., Oien, K.A., Siddiqui, N., Curto-Garcia, J., Brown, R. (2005) Demethylation of the MCJ gene in stage III/IV epithelial ovarian cancer and response to chemotherapy. Gynecol Oncol 97, 898-903. (Pubitemid 40824663)
46. Czekierdowski, A., Czekierdowska, S., Wielgos, M., Smolen, A., Kaminski, P., Kotarski, J. (2006) The role of CpG islands hypomethylation and abnormal expression of neuronal protein synuclein-gamma (SNCG) in ovarian cancer. Neuro Endocrinol Lett 27, 381-386. (Pubitemid 44390076)
47. Gupta, A., Godwin, A.K., Vanderveer, L., Lu, A., Liu, J. (2003) Hypomethylation of the synuclein gamma gene CpG island promotes its aberrant expression in breast carcinoma and ovarian carcinoma. Cancer Res. 63, 664-673. (Pubitemid 36158146)
48. Yao, X., Hu, J.F., Li, T., Yang, Y., Sun, Z., Ulaner, G.A., Vu, T.H., Hoffman, A.R. (2004) Epigenetic regulation of the taxol resistance-Associated gene TRAG-3 in human tumors. Cancer Genet Cytogenet 151, 1-13. (Pubitemid 38569630)
49. Woloszynska-Read, A., James, S.R., Link, P.A., Yu, J., Odunsi, K., Karpf, AR. (2007) DNA methylation-dependent regulation of BORIS/CTCFL expression in ovarian cancer. Cancer Immun 7, 21.
50. Murphy, S.K., Huang, Z., Wen, Y., Spillman, M.A., Whitaker, R.S., Simel, L.R., Nichols, T.D., Marks, J.R., Berchuck, A. (2006) Frequent IGF2/H19 domain epigenetic alterations and elevated IGF2 expression in epithelial ovarian cancer. Mol. Cancer Res. 4, 283-292.
51. Litkouhi, B., Kwong, J., Lo, C.M., Smedley, J.G., III, McClane, B.A., Aponte, M., Gao, Z., Sarno, J.L., Hinners, J., Welch, W.R., Berkowitz, R.S., Mok, S.C., Garner, E.I. (2007) Claudin-4 overexpression in epithelial ovarian cancer is associated with hypomethylation and is a potential target for modulation of tight junction barrier function using a C-Terminal fragment of Clostridium perfringens enterotoxin. Neoplasia 9, 304-314. (Pubitemid 46608297)
52. Florl, A.R., Lower, R., Schmitz-Drager, B.J., Schulz, W.A. (1999) DNA methylation and expression of LINE-1 and HERV-K provirus sequences in urothelial and renal cell carcinomas. Br J Cancer 80, 1312-1321. (Pubitemid 29308598)
53. Lorincz, M.C., Schubeler, D., Groudine, M. (2001) Methylation-mediated proviral silencing is associated with MeCP2 recruitment and localized histone H3 deacetylation. Mol. Cell Biol. 21, 7913-7922. (Pubitemid 33051784)
54. Lander, E.S., Linton, L.M., Birren, B., Nusbaum, C., Zody, M.C., Baldwin, J., et al. (2001) Initial sequencing and analysis of the human genome. Nature 409, 860-921. (Pubitemid 32165345)
55. Pattamadilok, J., Huapai, N., Rattanatanyong, P., Vasurattana, A., Triratanachat, S., Tresukosol, D., Mutirangura, A. (2008) LINE-1 hypomethylation level as a potential prognostic factor for epithelial ovarian cancer. Int J Gynecol Cancer 18, 711-717. (Pubitemid 352020191)
56. Menendez, L., Benigno, B.B., McDonald, J.F. (2004) L1 and HERV-W retrotransposons are hypomethylated in human ovarian carcinomas. Mol. Cancer 3, 12.
57. Qu, G., Dubeau, L., Narayan, A., Yu, M.C., Ehrlich, M. (1999) Satellite DNA hypomethylation vs. overall genomic hypomethylation in ovarian epithelial tumors of different malignant potential. Mutat Res 423, 91-101. (Pubitemid 29073654)
58. Widschwendter, M., Jiang, G., Woods, C., Muller, H.M., Fiegl, H., Goebel, G., Marth, C., Muller-Holzner, E., Zeimet, A.G., Laird, P.W., Ehrlich, M. (2004) DNA hypomethylation and ovarian cancer biology. Cancer Res. 64, 4472-4480. (Pubitemid 38856918)
59. Zhang, K., Dent, S.Y. (2005) Histone modifying enzymes and cancer: Going beyond histones. J Cell Biochem 96, 1137-1148. (Pubitemid 41681856)
60. Santos-Rosa, H., Caldas, C. (2005) Chromatin modifi er enzymes, the histone code and cancer. Eur J Cancer 41, 2381-2402. (Pubitemid 41540617)
61. LaVoie, H.A. (2005) Epigenetic control of ovarian function: The emerging role of histone modifi cations. Mol Cell Endocrinol 243, 12-18. (Pubitemid 41572274)
62. Ozdag, H., Teschendorff, A.E., Ahmed, A.A., Hyland, S.J., Blenkiron, C., Bobrow, L., Veerakumarasivam, A., Burtt, G., Subkhankulova, T., Arends, M.J., Collins, V.P., Bowtell, D., Kouzarides, T., Brenton, J.D., Caldas, C. Differential expression of selected histone modifi er genes in human solid cancers. BMC Genomics 7, 90.
63. Izutsu, N., Maesawa, C., Shibazaki, M., Oikawa, H., Shoji, T., Sugiyama, T., Masuda, T. (2008) Epigenetic modifi cation is involved in aberrant expression of class III beta-Tubulin, TUBB3, in ovarian cancer cells. Int J Oncol 32, 1227-1235.
64. Mirza, A., McGuirk, M., Hockenberry, T.N., Wu, Q., Ashar, H., Black, S., Wen, S.F., Wang, L., Kirschmeier, P., Bishop, W.R., Nielsen, L.L., Pickett, C.B., Liu, S. (2002) Human survivin is negatively regulated by wild-Type p53 and participates in p53-dependent apoptotic pathway. Oncogene 21, 2613-2622. (Pubitemid 34478319)
65. Fu, Y., Campbell, E.J., Shepherd, T.G., Nachtigal, M.W. (2003) Epigenetic regulation of proprotein convertase PACE4 gene expression in human ovarian cancer cells. Mol. Cancer Res. 1, 569-576. (Pubitemid 36706344)
66. Honda, H., Pazin, M.J., Ji, H., Wernyj, R.P., Morin, P.J. (2006) Crucial roles of Sp1 and epigenetic modifi cations in the regulation of the CLDN4 promoter in ovarian cancer cells. J Biol. Chem. 281, 21433-21444. (Pubitemid 44115482)
67. Caslini, C., Capo-chichi, C.D., Roland, I.H., Nicolas, E., Yeung, A.T., Xu. X.X. (2006) Histone modifi cations silence the GATA transcription factor genes in ovarian cancer. Oncogene 25, 5446-5461. (Pubitemid 44330287)
68. Jin, K.L., Pak. J.H., Park, J.Y., Choi, W.H., Lee, J.Y., Kim, J.H., Nam, J.H. (2008) Expression profile of histone deacetylases 1, 2 and 3 in ovarian cancer tissues. J Gynecol Oncol 19, 185-190.
69. Strait, K.A., Dabbas, B., Hammond, E.H., Warnick, C.T., Iistrup, S.J., Ford, C.D. (2002) Cell cycle blockade and differentiation of ovarian cancer cells by the histone deacetylase inhibitor trichostatin A are associated with changes in p21, Rb, and Id proteins. Mol. Cancer Ther 1, 1181-1190.
70. Lopez, J., Percharde, M., Coley, H.M., Webb, A., Crook, T. (2009) The context and potential of epigenetics in oncology. Br J Cancer 100, 571-577.
71. Schickel, R., Boyerinas, B., Park, S.M., Peter, M.E. (2008) MicroRNAs: Key players in the immune system, differentiation, tumorigenesis and cell death. Oncogene 27, 5959-5974.
72. Iorio, M.V., Visone, R., Di, L.G., Donati, V., Petrocca, F., Casalini, P., Taccioli, C., Volinia, S., Liu, C.G., Alder, H., Calin, G.A., Menard, S., Croce, C.M. (2007) MicroRNA signatures in human ovarian cancer. Cancer Res. 67, 8699-8707. (Pubitemid 47437445)
73. Yang, H., Kong, W., He, L., Zhao, J.J., O'Donnell, J.D., Wang, J., Wenham, R.M., Coppola, D., Kruk, P.A., Nicosia, S.V., Cheng, J.Q. (2008) MicroRNA expression profi ling in human ovarian cancer: MiR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res. 68, 425-433. (Pubitemid 351380068)
74. Lee, C.H., Subramanian, S., Beck, A.H., Espinosa, I., Senz, J., Zhu, S.X., Huntsman, D., van de Rijn, M., Gilks, CB. (2009) MicroRNA profi ling of BRCA1/2 mutationcarrying and non-mutation-carrying highgrade serous carcinomas of ovary. PLoS One 4, e7314.
75. Corney, D.C., Hwang, C.I., Matoso, A., Vogt, M., Flesken-Nikitin, A., Godwin, A.K., Kamat, A.A., Sood, A.K., Ellenson, L.H., Hermeking, H., Nikitin, A.Y. (2010) Frequent downregulation of miR-34 family in human ovarian cancers. Clin. Cancer Res. 16, 1119-1128.
76. Teschendorff, A.E., Menon, U., Gentry-Maharaj, A., Ramus, S.J., Gayther, S.A., Apostolidou, S., Jones, A., Lechner, M., Beck, S., Jacobs, I.J., Widschwendter, M. (2009) An epigenetic signature in peripheral blood predicts active ovarian cancer. PLoS One 4, e8274.
77. Laird PW. (2003) The power and the promise of DNA methylation markers. Nat Rev Cancer 3, 253-266. (Pubitemid 37328861)
78. Collins, Y., Dicioccio, R., Keitz, B., Lele, S., Odunsi, K. (2006) Methylation of deathassociated protein kinase in ovarian carcinomas. Int J Gynecol Cancer 16 Suppl 1, 195-199.
79. Chou, J.L., Su, H.Y., Chen, L.Y., Liao, Y.P., Hartman-Frey, C., Lai, Y.H., Yang, H.W., Deatherage, D.E., Kuo, C.T., Huang, Y.W., Yan, P.S., Hsiao, S.H., Tai, C.K., Lin, H.J., Davuluri, R.V., Chao, T.K., Nephew, K.P., Huang, T.H., Lai, H.C., Chan, M.W. (2010) Promoter hypermethylation of FBXO32, a novel TGF-beta/SMAD4 target gene and tumor suppressor, is associated with poor prognosis in human ovarian cancer. Lab Invest 90, 414-425.
80. Wiley, A., Katsaros, D., Chen, H., Rigault de la Longrais, I.A., Beeghly, A., Puopolo, M., Singal, R., Zhang, Y., Amoako, A., Zelterman, D., Yu, H. (2006) Aberrant promoter methylation of multiple genes in malignant ovarian tumors and in ovarian tumors with low malignant potential. Cancer 107, 299-308. (Pubitemid 44036559)
81. Chan, M.W., Wei, S.H., Wen, P., Wang, Z., Matei, D.E., Liu, J.C., Liyanarachchi, S., Brown, R., Nephew, K.P., Yan, P.S., Huang, T.H. (2005) Hypermethylation of 18S and 28S ribosomal DNAs predicts progressionfree survival in patients with ovarian cancer. Clin. Cancer Res. 11, 7376-7383. (Pubitemid 41507697)
82. Wei, S.H., Balch, C., Paik, H.H., Kim, Y.S., Baldwin, R.L., Liyanarachchi, S., Li, L., Wang, Z., Wan, J.C., Davuluri, R.V., Karlan, B.Y., Gifford, G., Brown, R., Kim, S., Huang, T.H., Nephew, K.P. (2006) Prognostic DNA methylation biomarkers in ovarian cancer. Clin. Cancer Res. 12, 2788-2794.
83. Muller, H.M., Millinger, S., Fiegl, H., Goebel, G., Ivarsson, L., Widschwendter, A., Muller-Holzner, E., Marth, C., Widschwendter, M. (2004) Analysis of methylated genes in peritoneal fl uids of ovarian cancer patients: A new prognostic tool. Clin Chem 50, 2171-2173. (Pubitemid 39425864)
84. Wurz, K., Garcia, R.L., Goff, B.A., Mitchell, P.S., Lee, J.H., Tewari, M., Swisher, E.M. (2010) MiR-221 and MiR-222 alterations in sporadic ovarian carcinoma: Relationship to CDKN1B, CDKNIC and overall survival. Genes Chromosomes Cancer 49, 577-584.
85. Leskela, S., Leandro-Garcia, L.J., Mendiola, M., Barriuso, J., Inglada-Perez, L., Munoz, I., Martinez-Delgado, B., Redondo, A., de Santiago, J., Robledo, M., Hardisson, D., Rodriguez Antona, C. (2010) miR-200 family controls {beta}-Tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients. Endocr Relat Cancer .
86. Wei, Y., Xia, W., Zhang, Z., Liu, J., Wang, H., Adsay, N.V., Albarracin, C., Yu, D., Abbruzzese, J.L., Mills, G.B., Bast, R.C. Jr, Hortobagyi, G.N., Hung, MC. (2008) Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers. Mol Carcinog 47, 701-706.
87. Weichert, W., Denkert, C., Noske, A., rb-Esfahani, S., Dietel, M., Kalloger, S.E., Huntsman, D.G., Kobel, M. (2008) Expression of class I histone deacetylases indicates poor prognosis in endometrioid subtypes of ovarian and endometrial carcinomas. Neoplasia 10, 1021-1027.
88. Strathdee, G., MacKean, M.J., Illand, M., Brown, R. (1999) A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene 18, 2335-2341. (Pubitemid 29192710)
89. Plumb, J.A., Strathdee, G., Sludden, J., Kaye, S.B., Brown, R. (2000) Reversal of drug resistance in human tumor xenografts by 2 -deoxy-5-Azacytidine- induced demethylation of the hMLH1 gene promoter. Cancer Res. 60, 6039-6044.
90. Brown, R., Hirst, G.L., Gallagher, W.M., McIlwrath, A.J., Margison, G.P., van der Zee, A.G., Anthoney, D.A. (1997) hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents. Oncogene 15, 45-52. (Pubitemid 27348095)
91. Hofstetter, B., Niemierko, A., Forrer, C., Benhattar, J., Albertini, V., Pruschy, M., Bosman, F.T., Catapano, C.V., Ciernik, I.F. (2010) Impact of genomic methylation on radiation sensitivity of colorectal carcinoma. Int J Radiat Oncol Biol Phys 76, 1512-1519.
92. Fu, S., Hu, W., Iyer, R., Kavanagh, J.J., Coleman, R.L., Levenback, C.F., Sood, A.K., Wolf, J.K., Gershenson, D.M., Markman, M., Hennessy, B.T., Kurzrock, R., Bast, R.C. Jr. (2010) Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinumresistant or platinum-refractory epithelial ovarian cancer. Cancer .
93. Su, H.Y., Lai, H.C., Lin, Y.W., Liu, C.Y., Chen CK, Chou YC, Lin SP, Lin WC, Lee HY, Yu MH. (2010) Epigenetic silencing of SFRP5 is related to malignant phenotype and chemoresistance of ovarian cancer through Wnt signaling pathway. Int J Cancer 127, 555-567.
94. Lee, P.S., Teaberry, V.S., Bland, A.E., Huang, Z., Whitaker, R.S., Baba, T., Fujii, S., Secord, A.A., Berchuck, A., Murphy, S.K. (2010) Elevated MAL expression is accompanied by promoter hypomethylation and platinum resistance in epithelial ovarian cancer. Int J Cancer 126, 1378-1389.
95. Taniguchi, T., Tischkowitz, M., Ameziane, N., Hodgson, S.V., Mathew, C.G., Joenje, H., Mok, S.C., D'Andrea, A.D. (2003) Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med 9, 568-574. (Pubitemid 36597103)
96. Boren, T., Xiong, Y., Hakam, A., Wenham, R., Apte, S., Chan, G., Kamath, S.G., Chen, D.T., Dressman, H., Lancaster, JM. (2009) MicroRNAs and their target messenger RNAs associated with ovarian Cancer Res.ponse to chemotherapy. Gynecol Oncol 113, 249-255.
97. Yang, N., Kaur, S., Volinia, S., Greshock, J., Lassus, H., Hasegawa, K., Liang, S., Leminen, A., Deng, S., Smith, L., Johnstone, C.N., Chen, X.M., Liu, C.G., Huang, Q., Katsaros, D., Calin, G.A., Weber, B.L., Butzow, R., Croce, C.M., Coukos, G., Zhang, L. (2008) MicroRNA microarray identifi es Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Cancer Res. 68, 10307-10314.
98. Jones, P.A., Baylin, SB. (2007) The epigenomics of cancer. Cell 128, 683-692. (Pubitemid 46273572)
99. Esteller, M. (2008) Epigenetics in cancer. N. Engl. J. Med. 358, 1148-1159.
100. Li, Y., Hu, W., Shen, D.Y., Kavanagh, J.J., Fu, S. (2009) Azacitidine enhances sensitivity of platinum-resistant ovarian cancer cells to carboplatin through induction of apoptosis. Am. J. Obstet Gynecol 200, 177-179.
101. Lenzi, R., Frost, P., Abbruzzese, J.L. (1994) Modulation of cisplatin resistance by 2 ¢ -deoxy-5-Azacytidine in human ovarian tumor cell lines. Anticancer Res 14, 247-251. (Pubitemid 24132120)
102. Balch, C., Yan, P., Craft, T., Young, S., Skalnik, D.G., Huang, T.H., Nephew, K.P. (2007) Antimitogenic and chemosensitizing effects of the methylation inhibitor zebularine in ovarian cancer. Mol. Cancer Ther 4, 1505-1514. (Pubitemid 41556432)
103. Takai, N., Narahara. H. (2007) Human endometrial and ovarian cancer cells: histone deacetylase inhibitors exhibit antiproliferative activity, potently induce cell cycle arrest, and stimulate apoptosis. Curr Med Chem 14, 2548-2553. (Pubitemid 350018467)
104. Modesitt, S.C., Sill, M., Hoffman, J.S., Bender, D.P. (2008) A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 109, 182-186.
105. Plumb, J.A., Finn, P.W., Williams, R.J., Bandara, M.J., Romero, M.R., Watkins, C.J,, La Thangue, N.B., Brown, R. (2003) Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol. Cancer Ther 2, 721-728.
106. Arts, J., Angibaud, P., Marien, A., Floren, W., Janssens, B., King, P., van Dun, J., Janssen, L., Geerts, T., Tuman, R.W., Johnson, D.L., Andries, L., Jung, M., Janicot, M., van Emelen, K. (2007) R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies. Br J Cancer 97, 1344-1353. (Pubitemid 350114783)
107. Takai, N., Ueda, T., Nishida, M., Nasu, K., Narahara, H. (2006) A novel histone deacetylase inhibitor, Scriptaid, induces growth inhibition, cell cycle arrest and apoptosis in human endometrial cancer and ovarian cancer cells. Int J. Mol. Med. 17, 323-329.
108. Shi, H., Wei, S.H., Leu, Y.W., Rahmatpanah, F., Liu, J.C., Yan, P.S., Nephew, K.P., Huang, T.H. (2003) Triple analysis of the cancer epigenome: An integrated microarray system for assessing gene expression, DNA methylation, and histone acetylation. Cancer Res. 63, 2164-2171. (Pubitemid 36538622)
109. Steele, N., Finn, P., Brown, R., Plumb, J.A. (2009) Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo. Br J Cancer , 100, 758-763.